A retrospective comparison suggests fluorine-18 PSMA-1007 PET/CT produces urinary bladder activity comparable to gallium-68 PSMA-11, potentially complicating lesion interpretation for recurrent prostate cancer. The study found PSMA-1007 frequently generated urinary bladder activity at levels similar to PSMA-11, which can obscure adjacent lesions. That matters for restaging workflows where local recurrence sites may sit near the bladder or prostate bed. Separately, the same dataset includes an additional retrospective finding that fluorocholine PET/CT can identify recurrences even after negative PSMA scans—supporting an emerging pattern of using alternative tracers when PSMA sensitivity is limited.